Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecast to 2017 Esophageal Cancer Therapeutics Market is forecast to Show High Growth Until 2017 GlobalData estimates that the global esophageal cancer therapeutics market was valued at $243.8m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 14% over the next seven years, to reach $594.7m by 2017. This fast growth is primarily attributed to the strong pipeline and onset of four promising molecules from 2014 onwards. The HER-2 expressing patients have access to Herceptin (transtuzumab) which is approved for HER2-overexpressing metastatic gastroesophageal (GE) junction adenocarcinoma along with some widely used off-label drugs such as cisplatin and capecitabine and ECF (epirubicin,cisplatin and 5-FU) which have gone off-patent. GlobalData analysis shows that the esophageal cancer therapeutics pipeline is strong, with 35 molecules in various phases of clinical development, including 31 first-in-class molecules. The four promising firstinclass products such as Avastin (bevacizumab), Erbitux (cetuximab), ramucirumab and Tykerb (lapitinib) in late stage pipeline are expected to hit the market around 2014. These products possess mechanisms of action different from currently used drugs. Thus the pipeline for the esophageal cancer therapeutics market is strong. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Esophageal-CancerTherapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017 The esophageal cancer therapeutics market is represented by Herceptin and some off-label drugs. Cisplatin, Xeloda (capecitabine) and ECF are mainly used drugs for treating esophageal cancer. Paclitaxel and carboplatin, 5-FU and leucovorin are also used but they have low response rates. Herceptin from Genetech/Roche is prescribed as the first line and second line form of drug therapy for the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma patients. There are no other drugs which have been approved for non HER-2 overexpressing patients of esophageal cancer. Any drug that could successfully cater to this untreated patient segment is expected to reap revenues from the esophageal cancer therapeutics market. GlobalData, the industry analysis specialist, has released its new report, “Esophageal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017�. The report is an essential source of information and analysis on the global Esophageal Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Esophageal Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Esophageal Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Esophageal-Cancer-Therapeutics-PipelineAssessment-and-Market-Forecasts-to-2017 Visit our report store: http://www.globaldata.com/reportstore For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782